Search results
Results from the WOW.Com Content Network
Irinotecan is a hydrophilic compound with a large volume of distribution (400 L/m 2). [20] [21] At physiological pH, irinotecan and its active metabolite ethyl-10-hydroxy-camptothecin (SN-38) are present in two pH-dependent equilibrium isoforms; the anti tumor active lactone ring which hydrolyzed to the carboxylate isoform. [21]
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
The approval was based on the results of the RAISE trial, a phase III study, which compared ramucirumab plus irinotecan, folinic acid, and 5-fluorouracil to FOLFIRI alone. [ 13 ] In May 2019, ramucirumab was approved by FDA as a single agent treatment for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of > 400 ng ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations.In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy.
This multiphase trial aimed to further evaluate the safety of tolerability of Abituzumab in combination therapy with cetuximab and irinotecan in the Phase I portion of the trial. [8] Cetixumab, a monoclonal antibody, that targets epidermal growth factor receptor (EGFR), and irinotecan, a topoisomerase I inhibitor, can be used in combination as ...
Combined small cell lung carcinoma (or c-SCLC) is a form of multiphasic lung cancer that is diagnosed by a pathologist when a malignant tumor, arising from transformed cells originating in lung tissue, contains a component of small cell lung carcinoma (SCLC) mixed with one or more components of any histological variant of non-small cell lung carcinoma (NSCLC) in any relative proportion.
Adjuvant treatment in patients with stage III colon cancer is recommended [2] for 12 cycles, every two weeks. The recommended dose schedule is as follows: Day 1: Oxaliplatin 85 mg/m 2 intravenous (IV) infusion in 250-500 mL D5W and leucovorin 200 mg/m 2 IV infusion in D5W administered concurrently over 120 minutes in separate bags using a Y-line, followed by fluorouracil (5-FU) 400 mg/m 2 IV ...
irinotecan (180 mg/m 2 IV over 90 minutes) concurrently with folinic acid (400 mg/m 2 [or 2 x 250 mg/m 2] IV over 120 minutes) followed by fluorouracil (400–500 mg/m 2 IV bolus) then fluorouracil (2400–3000 mg/m 2 intravenous infusion over 46 hours). This cycle is typically repeated every two weeks.